GlaxoSmithKline says Novartis deal could lead to more disposals

GlaxoSmithKline said the group's deal with Novartis narrowed its focus on the key areas of vaccines, respiratory, consumer and HIV medicines, and could be followed by the disposal of its portfolio of older drugs.